Concepedia

Merlin Efraim

ME

Statistics

Publications

3

Citations

53

H-Index

3

Active since

2019

Affiliations

Massachusetts General Hospital(Current)

University Hospital St. Marina

Barts Health NHS Trust

Royal London Hospital

University Hospital Hradec Králové

Merlin Efraim is an author at Massachusetts General Hospital specializing in medicine, platelet physiology, and bruton's tyrosine kinase inhibitors.

ORCID

Publications per year

2019–2024

3

Publications

3

Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia

David J. Kuter, Merlin Efraim, Lachezar H. Bogdanov et al. · Blood Advances · 2024 · 22 citations · Full text

, , +14

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, Eun‐Ju Lee et al. · Blood · 2019 · 16 citations

, , +11

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

David J. Kuter, Merlin Efraim, Vickie McDonald et al. · Blood · 2020 · 15 citations

, , +15

1–3 of 3